Speakers

More than 20 years of experience in pharmaceutical companies, with strong research, pre-clinical and clinical safety expertize in different therapeutic areas. For 10 years, acted as project/ team leader and laboratory head, leading various pre-clinical and clinical therapeutic...

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Düsseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M...

DR. SAMEER AWSARE is an Associate Executive Director for The Permanente Medical Group in charge of Pharmacy, Adult and Family Medicine, Mental Health, Risk Adjusted Coding, Revenue Cycle, Outside Medical Services, Pain Management and the Opioid Initiative.Dr. Awsare joined the Permanente Medical...

Carla C. Baan, PhD, is professor and head of the Nephrology & Transplantation Laboratory at Erasmus Medical Center, University Hospital Rotterdam, The Netherlands. Dr Baan obtained her doctorate from Erasmus University, The Netherlands.Her position involves the supervision of doctorate research ...

Marina joined Roche in 2010 and currently heads one of the Cancer Immunotherapy Departments at the Roche Innovation Center Zurich (RICZ). Marina and her team are dedicated to the characterization of the activity of different anti-cancer therapeutic agents including T-cell bispecific antibodies...

Martin obtained a PhD in Biochemistry from the University of Konstanz in a joint program with the University of Michigan. After postdoctoral training at the University of Washington, Martin joined Amunix Pharmaceuticals to work on long-acting protein therapeutics. In his current role at Roche, he...

Dr George Badescu is Vice President Scientific Affairs at Heidelberg Pharma and has over 15 years of experience in the biotechnology sector. He most recently served as Vice President Scientific Affairs at Abzena Plc where he led the scientific promotion and commercialization of Abzena’s...

I obtained a BSc in Biochemisty and did a PhD in Biochemisty at the National Institute of Medical Research, University College London. I then went onto do a number of post-doctoral studies with Prof David Beach at University College London, Prof Ashok Venkitaraman at the University of Cambridge and ...

A Medical professional with specialization in M.D. Clinical Pharmacology with 18 years of Pharma/Biopharma experience; Currently working as Vice President & Head– Medical, Clinical & Regulatory affairs for Wockhardt , Mumbai ; Earlier worked for Intas Pharma Ltd (15 years ) & Alembic (2 ...

Dr. Barnum is the Director of Neuroscience at INmune Bio, Inc. Dr. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academia and industry, including Emory University, FPRT Bio., SonosBio, and Takeda Pharmaceuticals. ...

Amrik has a PhD in biochemistry/protein engineering from the University of Leicester after which he spent 6 years at the Institute of Biotechnology, Cambridge University investigating bacterial pathways involved with the metabolism of illicit drugs and high explosives. In 2002, Amrik joined...

Dr. Bateman is currently Scientific Associate Vice President and the Scientific Lead for Bioanalysis in the Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism at Merck & Co. where he has worked for over 21 years.  He is the co-founder of the Merck Smart Trials initiative aimed ...

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology...

Dr Philip Beer is a physician scientist and precision oncology specialist who holds diverse roles across the healthcare, academic and commercial sectors, united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. Philip is currently working with the NHS...

Dr. Roger R. Beerli (CSO, NBE-Therapeutics AG) has over 20 years of experience in the discovery, engineering and preclinical development of antibody-based therapeutics. Before he joined NBE-Therapeutics AG, he led therapeutic antibody development programs at Cytos AG, Switzerland, and later at...

Stephen Beers joined the University of Southampton, Faculty of Medicine in 2002. His research group is interested in how antibodies work to result in tumour regression. Their research is currently focused on how host factors such as the tumour microenvironment and obesity/nutrition affect cancer...

Gustaf is an administrator / health economist with the Stockholm County Council, which is the regional authority responsible for providing health care in the Stockholm region. He coordinates the introduction of biosimilars in Stockholm. Before joining the Stockholm County Council four years ago he...

Mehdi Benchoufi is an Assistant Professor in Epidemiology in Clinical Epidemiology Center, at Hôtel Dieu Hospital, with Pure Mathematics and Computer Science background. His main interests are on the augmentation of healthcare by new technologies, and Open Science as an inclusive tool to improve...

Guillaume began his studies at the High Preparatory School in Biology in France, from which he holds MSc in Biotechnology in 2012. He worked four years for Novartis and UCB where he worked at the Center of Expertise for Biologics in Switzerland. Currently working as a Marie Curie Early stage...

Alain Bindels is an experienced Design Thinking facilitator, who leads an Innovation task force at Roche, supporting different business units to adopt innovation. He is interested in patient centric design of the healthcare industry, using new available technologies. He is applying the Design...

2016 PhD "Optimization of recombinant protein expression in insect cells" at the Helmholtz Center for Infection Research (Braunschweig, Germany)10.2016-09.2018 Head of the recombinant protein expression facility at the Rudolf Virchow Centre (Würzburg, Germany)since 10.2018 Habilitation at ...

A physician by training and an expert in immunobiology and drug development, Ezio Bonvini is the Senior Vice President of Research and Chief Scientific Officer at MacroGenics, Inc., which he joined in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics...

Patrick Bulau is principal scientist leading a team performing physico-chemical analyses with special focus on mass spectrometric technologies at Roche Pharma Technical Development in Penzberg, Germany. In addition to his responsibility for the analytics of drug substance development products he is ...

Dr Brian Champion is Chief Scientific Officer and member of the Executive Management Team at PsiOxus Therapeutics Ltd, Oxford, UK where he is leading the scientific team in the development of novel oncolytic virus-based, Tumor-Specific Immunogene (T-SIGn) therapies for the treatment of cancer.   He ...

Andrei Chapoval is currently a Director of Russian-American Anti-Cancer Center at Altai State University and Associate Professor at Center for Innovation in Medicine, Biodesign Institute of Arizona State University. He obtained his PhD in Immunology from Institute for Human Morphology...

Dr Veeren Chauhan is a Research Fellow in the Advanced Materials & Healthcare Technologies (AMHT) division at the School of Pharmacy, University of Nottingham. He is currently working as part of the EPSRC Future Targeted Healthcare Manufacturing Hub, aiming to develop transformative solutions...

Partha Chowdhury is Senior Director in Sanofi Biologics Research, US. He joined Sanofi in 2017 and leads antibody discovery and technology development activities in Biologics discovery, research and development. He has been involved with antibody discovery, engineering and technology development...

•    PhD MD Hanne Rolighed Christensen•    Head of Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark•    Member of the National Council of Medicine•    Vice chairman of the Drug Committee, Capital Region•    Chairman of the association of the 5 Regional ...

Dr Vijay Chudasama (VC) is a Reader in the Chemistry department at University College London. He has won multiple prestigious prizes and awards (departmental, faculty, national and international) throughout his academic career such as the UCL Faculty of Mathematical and Physical Sciences Medal...

Steve Coats serves as AstraZeneca/MedImmune’s VP R&D and Product Development Team Leader. His work focuses on interacting with external investigators to initiate clinical trials that are investigator led at academic institutes. Dr. Coats is also a product development team leader where he leads...

In 2004 I have received my Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy). After a post-doc in cancer immunotherapy at the Ludwig Institute for Cancer Research (Lausanne branch) and later at Cytos Biotechnology (Zurich) I have joined the Roche...

Robin Curtis joined the Chemical Engineering and Analytical Science School at University of Manchester in 2003.  Previously he did his PhD at the University of California at Berkeley and post doctoral training at University of California Los Angeles and Rice University.  His current research is...

I received a Engineer & Master degree in Antibody and Cell Engineering from Reims University in 2004.I have ~15 years of relevant industrial experience: Sanofi (2006-present), Centelion formerly Gencell fully owned by Sanofi (2004-2006). My accomplishments in antibody drug development include...

Dr. Dahan completed his PhD in Molecular Immunology at the Technion in 2010. He served as a postdoctoral fellow in Cancer Immunology at the Laboratory of Prof. Jeffrey Ravetch at Rockefeller University in New York from 2013 until joining the faculty of the Weizmann Institute of Science in...

Eva Dahlén, Ph.D., is a life science professional with approximately 20 years of experience from the life science sector. Her current position is as Senior Director, Business Development at Alligator Bioscience. In this capacity, her responsibilities include business development and business...

Annick has over 15 years of experience in both pharma and academia in Australia, the USA, UK, Belgium and the Netherlands. She was trained as a neuroscientist (University of Amsterdam, NL) and acquired her PhD in Pharmacology at Utrecht University (NL). Her experience in assay development started...

Dr. Ruud de Wildt has more than 20 years of experience within the Biotech and Biopharmaceutical industry. His teams have delivered many therapeutic candidate molecules across several therapeutic areas including oncology, respiratory, infectious diseases and the immunology field. This includes...

I performed my master thesis in the Laboratory of mass spectrometry of Pr De Pauw in the University of Liege in collaboration with the drug metabolism and pharmacokinetics department of Janssen pharmaceutica. My task was to identify different modification sites on a model protein of different...

John leads Amgen’s Biologic Discovery function responsible for identifying large molecule therapeutic candidates in collaboration with all Amgen Therapeutic Areas, including the discovery of fully human antibody therapeutics using the company’s proprietary XenoMouse platform technology. John joined ...

Gundo Diedrich received his Ph.D. in Chemistry from the Max-Planck Institute for Molecular Genetics in Berlin. He completed his postdoctoral training in immunology at Yale University, and worked as a Research Scientist in antibody discovery at Targeted Molecules, diaDexus, and Medimmune. In...

Surjit Dixit, Ph.D., is the Chief Technology Officer of Zymeworks Inc. His responsibilities include the advancement of the ZymeCAD™ platform for computer aided therapeutic protein optimization and its application towards the development of novel molecular platforms and tailored therapeutic...

Maggie achieved her BSc pharmacy at Heriot Watt University, Edinburgh, and a diploma in clinical pharmacy from Strathclyde University in 1991. She has many years of experience as a hospital clinical pharmacist primarily in Scotland. She was Chief Pharmacist in Edinburgh in both the adult (West...

Before joining the EPO, Dr. Domingues completed a PhD degree in Protein Engineering at the European Molecular Biology Laboratory in Heidelberg in collaboration with the University of Utrecht, followed by post-doctoral work. She joined the EPO in October 2000 and worked as a Patent Examiner in the...

As R&D Director of GEROPHARM Roman establishing product development of the company’s portfolio.Joined GEROPHARM as a head of clinical trials department in Oct 2016. Successfully performed several clinical trials including hyperinsulinemic euglycemic clamps and bioequivalence, Phase III...

Dr. Birgit Dreier has been Senior Scientist in the group of Prof. Dr. A. Plückthun at the Department of Biochemistry, University of Zurich, for more than 10 years and is responsible for the organization, optimization and selection of DARPins (Designed Ankyrin Repeat Proteins) and other scaffold...

Jen has worked for GSK for over 10 years and in this time has gained experience working with a range of antibody formats including mAbs, dAbs, dAb fusions and mAb-dAbs. Recently her work has focused specifically on developability, developing screens for solubility of mAbs targeting high...

Dr Carolyn Edwards is a Principal Scientist and Project Leader at Crescendo Biologics, a company developing Humabody® VH domain antibodies for cancer. She is Pharmacology Lead in a drug development program for a novel bispecific tumour-targeted T-cell enhancer. Dr Edwards also leads a team of...

Meltem Elitas is a faculty member at Sabanci University Mechatronics Program since 2015. She was a postdoctoral research associate in the Bioengineering Department at Yale University, Connecticut, US. She worked with Prof. Rong Fan, developed microfluidic artificial tumor microenvironment assays to ...

Patient Engagement in Research Coordinator at Sant Joan de Déu Chidren’s Hospital (Spain). She has long experience in the field of the involvement of patients and families in research initiatives. She has also a personal story as a caregiver and patient advocate because is the sister of a young...

Stefan Ewert, Ph.D. joined Novartis in 2004 and holds the position of a Senior Investigator within the NIBR Biologics Center. He is responsible for antibody phage display selections done in Basel. Before joining Novartis he was instrumental in developing ESBATech’s scFv-based key technology. During ...

Dr. Shawn Fahl leads the cell biology and flow cytometry laboratories and consulting services for Discovery Life Sciences. Dr. Fahl trained at the University of Virginia and Fox Chase Cancer Center and has expertise in flow cytometric analysis, immunology, and cell biology.

Georg Fey. Degrees in physics and biochemistry. Post-doctoral training in tumor virology and molecular genetics. Team leader, Swiss Cancer Research Institute, Lausanne, CH. Lab Chief, Dept. of Immunology, Scripps Research Institute, La Jolla, CA, USA. Chairman of Genetics, University of...

Dr. Romano is currently working as Associate Professor in Biochemistry at the University of Naples “Federico II”. She received her Doctoral degree on Medicine and Surgery from the University of  Naples “Federico II”. She completed her Masters in Oncology and Immunology at the Universities of Naples ...

Figini has been involved in antibody production, characterization and engineering from the beginning of her career starting with the classic hybridoma technology and chimerization up to isolation of human antibodies from phage display library a revolutionary technology discovered in the early...

Jonny Finlay is the CEO of UltraHuman, an antibody drug discovery biotech in the UK that is developing a series of therapeutics for inflammation and oncology. Prior to co-founding UltraHuman, Jonny led research teams in Biologics Discovery at Pfizer and Wyeth, and carried out postdoctoral research...

Nicolas Fischer obtained a PhD in Biology from the Department of Molecular Biology University of Geneva on the structure and function of photosynthetic complexes. As a postdoctoral fellow he joined the Group of Sir Greg Winter at the MRC Department of Molecular Biology in Cambridge UK to study...

Patrick Garidel is currently employed as Head of Pharmaceutical and Protein Science at Boehringer Ingelheim Pharma GmbH & Co. KG. His activities are focused on the development biologics from the downstream process to drug product (liquid and solid formulations, freeze-drying). His expertise...

Hans-Peter has over 20 years of research and development experience in oncology, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies. He has been leading Pfizer’s Bioconjugates division as CSO, overseeing Pfizer’ s efforts in...

Jacob Glanville is an entrepreneur and computational immuno-Engineer. He developed the core business model, the research teams, and the technologies that enabled Distributed Bio to become profitable without investment. He has developed multiple seminal methods in the fields of high-throughput...

Marco Gobbi got his M.Sc. degree in Pharmacy at the University of  Milan in 1989.  After a fellowship spent in the Dept. of Pharmacology of the School of Pharmacy, University of London, he started his research activities in the laboratory of Neuropharmacology at the "Mario Negri"...

Ulf Grawunder is a Biotech entrepreneur with more than 15 years in the Biotech industry. He is CEO of NBE-Therapeutics which he founded in 2012. Prior to that, Ulf was co-founder of 4-Antibody, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as...

Emma is Head of Clinical Trials at the MS Society. She is responsible for developing and supporting the MS Society’s growing portfolio of clinical trials; collaborating with national and international funders (charity, government, other) to secure funding for MS clinical trials, the UK MS Clinical...

Dr. Greenberg leads a multi-disciplinary research and early development team delivering unique therapeutics derived from the immune repertoires of elite responder patients in multiple indications. Dr. Greenberg previously held positions as Senior Vice President for Translational Medicine at...

Keno Gutierrez, PhD, MBA, joined the Healthcare team as an Investment Director in 2017. Previously, he worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno was an associate at...

Christian P. R. Hackenberger completed his graduate studies in chemistry at the universities of Freiburg and UW Madison and his doctoral studies in 2003 at the RWTH Aachen. After a postdoctoral position at MIT with Barbara Imperiali, he started his own group at the Freie Universität Berlin in 2005...

Eric Halioua is a serial entrepreneur with strong managerial, technological, fund-raising and deal-making experience. Eric Halioua is President and CEO of PDC*line Pharma a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid...

Prior to Singapore Biotech, Dr. Hamedifar was the CEO of CinnaGen for 14 years. She was the founder of CinnaGen Group as well as CinnaGen’s seven sister companies. Under her leadership, she transformed the company from a diagnostic manufacturer to a global biopharmaceutical company, increasing...

Brenda Hann is the Director of Clinical Research Operations in the Stanford Cancer Clinical Trials Office at Stanford Cancer Institute.  The Cancer Clinical Trials Office provides central coordination and oversight of clinical staff to ensure consistent processes, regulatory compliance and...

As Director of Pharmacy, Matt works to monitor, evaluate, and improve the pharmacy plan performance of the Employers Health $1 billion PBM group purchasing programs with CVS Health, OptumRx and EnvisionRx. He works proactively with the organization’s more than 250 member employers to provide...

Guy joined Isogenica as CSO in 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development. At Isogenica, he leads the internal technology and product development, as well as drive scientific interactions...

Oliver Hill joined Apogenix in March 2006. He is an expert for protein engineering and protein expression technologies. Prior to his position at Apogenix, he headed the protein expression and purification group at Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany) from 1999 to 2006. At...

Dr. Soraya Hölper works as a Lab Head for Mass Spectrometry for Sanofi in Frankfurt am Main. She is acquainted with the analysis of complex therapeutic antibodies within the Biologics Research division. After studying biochemistry at the Goethe University of Frankfurt am Main, Soraya did her...

Dr. Yue Huang graduated from Beijing Medical University, China, then obtained his PhD from University of Minnesota, USA.  He also completed an executive MBA from Swiss Business School (SBS) in Switzerland. Dr. Huang has 17+ years of pharmaceutical industry experience, with specialties in the...

Caroline initially studied Biochemistry before specialising in Immunology during her PhD. Her thesis focused on developing methods for the production of antigen specific regulatory T cells using lentiviral gene transfer with the aim to treat autoimmunity.  In 2017 she joined the CAR mechanics group ...

An innovation, multi award-winning Clinical Operations and Consulting Expert with extensive experience and skills gained from international global assignments.  A blockchain advocate and patient engagement thought leader with over 17 years in the NHS on commission by the DOH and in Industry...

Dirk Jäger is the Managing and Medical Director of the National Center for Tumor Diseases (NCT) Heidelberg, Head of the Medical Oncology Department at the Heidelberg University Medical Center, and is Head of the Clinical Cooperation Unit Applied Tumor-Immunity at the German Cancer Research Center...

Following my PhD in Chemistry I moved to the Medical School (Birmingham) to initiate research on the structure and function of antibody molecules. Studies of the four human IgG subclasses revealed the profound impact that glycosylation has on structure and mechanisms of action, in vitro and in...

Martina completed her PhD in Medicinal Chemistry at the Karolinska Institute, before working as a Researcher at Roche Process Research and Supply unit, of the pre-clinical chemistry manufacturing controls department. She then went on to a role as a Senior Scientist at Novartis NBE Pharmaceutical...

Dr. Xiaona Jing (Director Global CMC & Pharmaceutical Development, NBE-Therapeutics AG), has managed multiple biopharmaceutical CMC projects various from early clinical to the commercial stage, with focus on innovative oncology products such as antibody and ADC.She is experienced in...

Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003.  Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently...

Colette has been part of Crescendo Biologics since 2012. She is responsible for the proprietary mouse platform and early discovery activities in Crescendo’s Humabody discovery pipeline.  Colette joined Crescendo from MedImmune where she was in the Department of Antibody Discovery and Protein...

Having spent nearly a decade in clinical research working for the National Health Service, Academia, the Institute for Health Research an now Pharma I have gained a vast knowledge of many of the sectors providing input into clinical trials within the UK. I have a lot of experience in managing study ...

Founded in October 2016 by Carine MOREL, Sylvain JULIEN and Geoffroy DE BETTIGNIES, e-Zyvec is a Biotech company devised by scientists to serve scientists. Rather to provide another service of ‘customized’ DNA molecules to biologists, we aim to offer an efficient and innovative partnership in...

Dr. Jennifer Jung works as Lab Head for Mass Spectrometry for Sanofi in Frankfurt am Main. She is analyzing therapeutic proteins within the Biologics Research division using mass spectrometry. She started her scientific career by studying biochemistry at the Goethe University in Frankfurt am...

Meelis Kadaja is active in the development and commercialization of technologies for biological therapeutics, antibodies, immunoassays and gene therapy. His previous research areas have been DNA viruses and adult tissue specific stem cells. He received MBA and Ph.D in the University of...

Anssi Kailaanmäki, PhD, is the Head of Immunotherapy at the newly-formed Kuopio Center for Gene and Cell Therapy (KCT), based in Kuopio, Finland. At KCT, Anssi leads the Immunotherapy Program that operates under the Cell Therapy Unit. KCT’s Immunotherapy Program aims to develop novel immune...

Maud Kamal, PhD is the scientific manager of the department of Drug Development and Innovation at Institut CurieShe manages and coordinates precision medicine and European projects at Institut Curie where she is also in charge of the scientific management of the Molecular Tumour Board. She is...

Dr. Hélène Kaplon completed a PharmD at the University of Lille in 2014. Since 2011, she has co-authored Acthera, a guide of Therapeutic Antibodies approved in the European Union written for pharmacy students and pursued her career in the immuno-oncology field. Beginning 2015, she started a PhD in...

Project manager of the International Clinical Trials Registry Platform (ICTRP) in the World Health Organization since 2011, expert in clinical trials database design, clinical trials registration & results and ethics committees information systems. Member of several international working groups ...

Andreas is co-founded Anaveon in April 2018, and previously was the Director of Autoimmunity, Transplantation & Inflammation, Novartis Institutes of  Biomedical Research, Basel Big Pharma experience in the discovery and development of immunomodulating drugs (26 years) Extensive BD&L...

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

Dr. Elisa Kieback has a scientific background with 15 years experience in immuno-oncology. After an academic career studying T cells and T cell receptors, she co-founded T-knife, a Berlin-based biotech start-up dedicated to develop tumor-specific receptors for T cell therapy, of which she is the...

Christian Klein, Distinguished Scientist is Head of Oncology Programs at the Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Switzerland specialized in the discovery, validation and preclinical development of antibody based cancer immunotherapies and bispecific...

Cecilie Knudsen is an industrial PhD student at the Tropical Pharmacology and Biotherapeutics Lab at the Technical University of Denmark and at BioPorto Diagnostics A/S. She is specialised in toxinology, antibody discovery, antivenom, and diagnostics, and is a co-founder of the start-up VenomAid...

Dr. Jiri Kovarik has more than 15 years of experience in drug R&D at the Novartis Institutes for Biomedical Research with focus on the generation of therapeutic antibodies for the treatment of inflammatory/auto-immune diseases. Before working in industry, his scientific activities included the...

Dan Bach Kristensen holds a Ph.D. in biology and B.Sc. degree in chemistry. Dan is specialized in protein chemistry and mass spectrometry, which he initially applied in the field of proteome research in Japan and later in Denmark. For the last 15 years Dan has been working with analytical...

The research of Peter Kristensen is centered on the technical development and application of methods that allow Darwinian evolution of proteins using directed evolution technologies. The main scientific contributions have more specifically been in the area of recombinant antibodies and methods of...

Dr. Anne Månsson Kvarnhammar earned her PhD 2009 at Lund University, Sweden, working on the immune response in allergic rhinitis. This area was further pursued during a postdoc position at Karolinska institutet. In 2012, Dr. Kvarnhammar joined Novo Nordisk, Denmark, working with developing models...

Dr. Lantto is a Project Director at Symphogen A/S, a Danish clinical late-stage antibody oncology-focused company. Dr. Lantto holds a Ph.D. in Immunotechnology from Lund University, Sweden, where he studied antibody evolution and repertoire development. Dr. Lantto has more than 20 years of...

Heinz Läubli is a physician scientist with clinical training and a specialisation in Medical Oncology. He is a senior attending physician at the University Hospital in Basel, Head of a clinical research group and Head of Glycobiology Research in the Cancer Immunology Laboratory in Basel. His...

Associate Professor Andreas Hougaard Laustsen heads the Tropical Pharmacology Lab at the Department of Biotechnology and Biomedicine, Technical University of Denmark. He is specialized in antibody discovery, toxinology, antivenom, and neglected tropical diseases. Andreas is an Advisor to the WHO’s...

Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He is a skillful immunologist, with many years of teaching and research expertise on gastrointestinal complications ...

Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 ...

Dr. Jeanette Leusen, received her PhD in 1995 at the University of Amsterdam, The Netherlands. She became associate professor and head of the immunotherapy group of the University Medical Center in Utrecht in 2006, and head of the UMAB facility in 2012. She has co-authored more than 100...

Xiaonan Li studied chemistry in PKU (China), holds a Ph.D. from Delft University of Technology (Netherlands) with specializations in Bio-separation Technology and has over 10-year experience in protein biochemistry. Currently, he is the lead scientist in the downstream processing department at...

Chris Lloyd is a Senior Scientist working in the Antibody Discovery and Protein Engineering (ADPE) group at MedImmune, Cambridge UK. He has over 15 years’ experience in the field of antibody engineering at MedImmune (and previously CAT), currently with an active interest in bispecific antibodies...

John Löfblom is associate professor at KTH Royal Institute of Technology. His current research focus is on method development for directed evolution of affinity proteins, proteases and aggregation inhibitors as well as engineering of small affinity proteins into multimeric formats for new modes of...

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, a clinical stage biotech company with innovative antibody discovery and engineering technologies. By utilizing its proprietary Dynamic Precision Library Platform (DPL) and SAFEbody™ technologies, Adagene is showcasing its...

Chris has recently joined Pancreatic Cancer UK from Versus Arthritis where he led on patient centricity, integrating the insight of people affected by arthritis in to the decision making of the research directorate. He has worked directly with a number of industry partners to co-deliver patient...

Jörg Mahlich is Head of Health Economics and Outcomes Research at Janssen pharmaceutical companies of Johnson and Johnson in Germany. In addition, he is Lecturer of Health Economics at the Economics Department of the University of Vienna and research affiliate at the Düsseldorf Institute for...

Dr. Mamula is a Professor of Medicine in the Yale University School of Medicine.  Dr. Mamula’s research interests are in investigating the early events involved with breaking immune tolerance to self proteins, both in autoimmune disease and in tumor biology.  Overall, it is the goal of Dr. Mamula’s ...

Andrea Marschall studied Molecular Biotechnology at Heidelberg University, gained a PhD in Stefan Dübel's lab on targeting antibodies into living cells, continuing with Postdoctoral research at the Helmholtz Centre for Infection Research in Braunschweig (Germany) and at Brandeis University in...

My interest in health and science led me to pursue a doctoral degree in Immunology, a field that I find fascinating. I initiated my scientific carrier studying the relationship between hormones and the immune system. Following the completion of my PhD studies I became interested in neuroimmunology...

As Head of Biology at Novimmune, Krzysztof is in charge of immuno-oncology antibody discovery. He holds a Ph.D. from the University of Lausanne.

Ivana is a certified MD who has spent over a decade in clinical research, gaining experience in various country, regional and global job roles at MSD. She holds a position of Global Operations Lead – Agreements, as well as the process ownership over site ready support with an accent on the...

Lamine is SVP & Head of Glenmark Biotherapeutics. Prior to joining Glenmark, Lamine held several leadership positions in the USA at Boehringer Ingelheim, Genomics Institute of Novartis Research Foundation (GNF), Novartis Vaccines and Centocor (Janssen) where he led and advanced several...

Christoph joined the European Molecular Biology Laboratory in Heidelberg, Germany, as a Principal Investigator in 2010, focusing on microfluidic technology for HTS and genomics. His lab is particularly interested in the development of droplet-based microfluidics for cell-based screens. Christoph is ...

Derek Mason worked as a process engineer in Denver, Colorado for 3 years before moving to Basel, Switzerland in 2015. Currently, he is finishing his PhD in the Laboratory for Systems and Synthetic Immunology at ETH Zurich’s Department of Biosystems Science and Engineering. Intrigued by recent...

Ali Mohamed, PhD, Vice President, CMC, Immatics US Inc. Formerly the senior director of manufacturing operations/ manufacturing development at Caladrius PCT (Now Hitachi Chemical Advanced Therapeutics Solutions). Dr. Mohamed has nearly 20 years of experience in process development and GMP...

Melissa is an Operational Intelligence Leader at F. Hoffmann - La Roche in Basel, where she supports recruitment and retention strategies in late stage development.  Her speciality has been helping teams build Recruitment and Retention strategies by implementing learnings around the patient’s...

Study of Biology in Bochum, GermanyPhD in Immunology/Allergy Research, Borstel, GermanyPost Doc in Cambridge, UK at the Babraham Institute with M. Brüggemann establishing transgenic mice expressing fully human antibodiesScientist in Cambridge, UK at the Babraham Institute with...

Aditya completed his doctoral studies at the University of Toronto, Canada, department of Medical Biophysics. He joined the Department of Immunology at Genentech as a post-doctoral fellow in the lab of Dr. Menno van Lookeren Campagne in 2011. Focusing on human genetics and the contribution of...

Isabelle Naëije has a Master in Sciences degree in bio-engineering (Free University of Brussels, Belgium). Her thesis was devoted to the study of the protein MxiC in the regulation of the type III secretion system of Shigella flexneri. She works for Novartis Pharma AG, Basel, Switzerland. She is an ...

Dario Neri was born in Rome on 1 May 1963.. He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral...

Johan Nilvebrant received his PhD in 2012 at the Royal Institute of Technology, Stockholm, Sweden. He was a postdoc with Sachdev Sidhu at the University of Toronto where he worked on new single-domain antibody library designs and ligand-mimicking antibodies. His current research focuses on protein- ...

Ahuva Nissim graduated in Molecular Immunology in Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed a phage display semi-synthetic human antibody library which has...

My research group is focused on protein engineering of calcium binding proteins for biotechnological applications. We apply structural biology analysis, proteomics tools and biophysical methods to develop new technology and our work is aimed at improving the molecular toolbox available to...

Christian Ohmann performed his university examination (1976) and graduation in mathematics together with an interim examination in medicine (1984). This was followed by a habilitation in Theoretical Surgery in 1997 and a professorship in 1993 at the Heinrich-Heine-University in...

Benjamí Oller-Salvia is Assistant Professor at IQS School of Engineering – Ramon Llull University in Barcelona (Spain). He obtained his PhD at the University of Barcelona, conducting research in Prof. Ernest Giralt’s laboratory at the Institute for Research in Biomedicine (IRB Barcelona). His PhD...

Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug...

Mareike Ostertag has extensive experience in the pharmaceutical industry. In over 16 years with Novartis, Dr. Ostertag held different roles with increasing responsibility within the company as well as with external industry- and non-industry partners. Roles included Technical Marketing, Global...

Tanja holds a PhD in Neurosciences from the University of Montréal (Canada). She then moved to Paris to pursue her research on metalloproteases as drug targets in academia before joining Pharmaleads in 2006 as Head of Biochemistry, characterizing metalloprotease and inhibitor activity in vitro and...

Raj is a trained Medical Doctor from Australia & Health Care Entrepreneur with close to 2 decades of experience in Strategies & Partnerships, Technologies and Product Management. He had the pleasure of working with tens of Global Enterprises in the space of Consumer Health Care, Device...

I am a Sr. Scientist in the Immunology Discovery group at Genentech Inc. in South San Francisco, Ca. I received my PhD in Immunology from Washington University in St. Louis from the laboratory of Dr. Andrew Chan. My thesis work identified a role for the adapter protein, BLNK, in murine and human B...

Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor.After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and...

Sue has a PhD in Human Cancer Genetics and had a high profile career working with Prof Sir Walter Bodmer mapping the first colorectal cancer gene. She worked on the Human Genome Project at UCL, Oxford and UCSF, USA. Since 1998 she specialized in Applied Health Research, Clinical Trials and...

Richard Peck studied medicine in the USA and obtained a Doctor of Philosophy from the University of Tennessee. Following a Post-Doc at the Biozentrum of the University of Basel (medical virology, molecular biology), he was employed by F. Hoffmann LaRoche, Basel as International Regulatory Affairs...

Thomas Pillow received his Ph.D from Stanford University in organic chemistry under the direction of Professor Paul Wender. Upon graduation he moved to Genentech in 2009 where he is currently a senior scientist in the discovery chemistry department leading Genentech’s effort on antibody-drug...

Nicolas Poirier earned his Ph.D. in Immunology at the European Center of Transplantation Sciences and Immunotherapy (CESTI) with guidance from immunotherapeutic-Transplant pioneer. He worked on the preclinical evaluation of novel therapeutic strategies modulating costimulation, immune checkpoint or ...

Dr. Anne Poupon is Senior Scientist at the CNRS, heading the group Biology and Bioinformatics of Signalling Systems. After MS degrees in Biochemistry and in Mathematics, she has obtained a PhD thesis on the conservation of hydrophobicity in globular proteins. Since then she has been developing...

Senior clinical research professional and project manager with versatile drug development and clinical research expertise. Interested in clinical research innovation and patient centricity. Strategic adviser for start-up companies and independent expert at the European Commission.

Christophe is responsible for directing and advancing the development of Oncorus’ next generation oncolytic viruses. An industry veteran, Christophe has nearly two decades drug discovery experience in immuno-oncology and a successful track record of building portfolio from target identification...

Dr Qasim Rafiq is an Associate Professor at University College London in Cell and Gene Therapy Bioprocessing. He is a multidisciplinary engineer working at the life science, engineering and commercial interfaces and his research focuses on the bioprocessing, automation and biomanufacture of...

Alexander Rau holds a master’s degree in Technical Biology from the University of Stuttgart, and he is a PhD student at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany. His research interest focuses on the development of multivalent and bispecific antibodies and their ...

Sai Reddy is an Associate Professor in the Department of Biosystems Science & Engineering, ETH Zurich, Switzerland. His research group uses methods in systems and synthetic biology to study and manipulate immune responses for applications in biotechnology, vaccination, and immunotherapy. Sai...

Dr. Nicolò Rigamonti received his Master degree in Molecular Biotechnology from the Milano-Bicocca University. He performed his master thesis at the Royal Institute of Technology (Stockholm), developing an affibody-based strategy for breast tumors. During his PhD studies in tumor...

Following studies in molecular biology and biochemistry at the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland, Dr. Roesli performed his PhD thesis in the lab of Prof. Dario Neri at the same university. After the subsequent PostDoc period, he led his own research group on...

Michelle Rosenzwajg is at the head of the immunomonitoring team of the Clinical Investigation Center in Biotherapy. She is involved in translational research towards a better understanding of immunopathologies and the development from bench to bedside of immunotherapies in the field of cancer and...

Karsten Roth leads the clinical development and pharmacovigilance teams at Mundipharma-Biologics, former Cinfa Biotech. He is responsible for the development and implementation of preclinical, clinical and post-approval clinical activities and oversees the pharmacovigilance activities at...

Kaspar Rufibach is a member of Roche's Methods, Collaboration, and Outreach group and located in Basel. He does methodological research, provides consulting to Roche statisticians and broader project teams, gives biostatistics trainings for statisticians and non-statisticians in- and...

Jack earned his Bachelor’s degree in Chemistry from Pomona College in 2000 and his Ph.D. in Chemistry from the University of Wisconsin – Madison in 2006.  His graduate work focused on the development of non-natural, oligomeric (beta-peptide) inhibitors of protein-protein interactions, leading to...

Alessandro Satta graduated at Università degli Studi di Milano in 2010 after performing the thesis research on the capability of self-assembling peptides to regenerate nervous cells after spinal cord injury. Then he started working since 2010 in the laboratory of Dr. M.Figini and Dr. S.Canevari in...

Dr Matthieu P Schapranow received a PhD in Software Engineering from University of Potsdam in Germany in 2012. He also received BSc and MSc degrees in Software Engineering, in 2006 and 2008, respectively from the Hasso Plattner Institute (HPI). Currently, he is Program Manager E-Health at the HPI...

Karoline W. Schjetne holds a PhD from Institute of Immunology, University of Oslo, followed by a postdoctoral scholarship where she also hospitalized as visiting researcher at Harvard Medical School. Karoline has worked in both biotech and big pharma industry within the area of immunotherapy and...

Head of Department Biologics-Research, German R&D organization, SanofiDr. Thorsten Schmidt joined Sanofi in 2002. He is currently the Head of the German Biologics Research Platform in the area of protein therapeutics. He is in this role since 2016 and responsible for a team of 60 scientists...

Darren Schofield, Ph.D., is a Senior Scientist within the Antibody Discovery and Protein Engineering Department, in the R&D BioPharmaceuticals Division at AstraZeneca, UK. He is a protein engineer who leads a small team responsible for the generation of candidate therapeutic biologic drugs...

Dr Nabila SEDDIKI is a Senior Lecturer at the Paris-Est Créteil University (UPEC). She holds an INSERM “Chaire d’Excellence en Immunologie et Maladies Infectieuses”. She joined the Vaccine Research Institute (Créteil, France) end of 2010. Before that she was a Research Fellow at the Centenary...

Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano...

Armin Sepp is Scientific Leader and GSK Associate Fellow at the Systems Modeling and Translational Biology group of GlaxoSmithKline where he is providing early stage project support for biotherapeutic projects covering mAbs, antibody fragments as well as cell and gene therapy products. His...

Dr Maryam Shariatzadeh is an interdisciplinary bioengineering scientist, and a qualified pharmacist whose project focuses on development of ODE mechanistic modelling for T cell therapy manufacture to offer cost effective solutions in T cells / CAR T cells bioprocessing / process control and...

Oliver Seifert holds a PhD in Molecular Biology from the University of Stuttgart and he is a Post-Doc at the Institute of Cell Biology and Immunology based at the University of Stuttgart, Germany. Research interests focus on the design and development of multivalent and multispecific antibody...

Born in San Francisco, California, grew up in Beverly Hills , Calif.. Attended UCLA and Juilliard School of Music (BSc and MSc in Music); came to Germany as opera singer and sang professionally for 5 years; studied medicine Uni Düsseldorf (doctorate)- specialist in Anesthesia, General Medicine and...

Dr. Arne Skerra is Full Professor at the Technical University of Munich, Germany, where he heads the Institute of Biological Chemistry. He holds a Diplom degree in Chemistry from the Technical University of Darmstadt and a PhD in Biochemistry from the Ludwig-Maximilians-University Munich. After...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

PhD in Biology,MsC in Biotechnology, MsC in Microbiology andGenetics, MsC in Environmental sciences, BS in Biology and BSin Biotechnology with 20 years of experience in the biotechnologyand bio-pharmaceutical industry. I developed as a professionalin the area of small...

Dr. Spycher is a PSI Founder Fellow at the Paul Scherrer Institute (PSI) Villigen (Switzerland) working on the site-specific modification of native antibodies. He is a co-founder of the PSI spin-off Araris Biotech AG, incorporated in January 2019, that is focused on ADCs and advancing the newly...

Denise Steckel has over 19 years of experience at Genentech in Operations Support, Quality and External Collaborations.   Currently Denise is the Technical Alliance Manager of the Collaboration Alliance Management group.  In this role Denise and her team ensure alignment of all CMC...

Daniel performed his undergraduate studies at the ETH Zürich and at the Imperial College London. During his PhD studies at the University of Zurich with Prof. Dr. Andreas Plückthun, Daniel established a novel in vitro selection system enabling the efficient selection of DARPin molecules on complex...

Anke is a Senior Researcher in Molecular Design Sciences/Integrated Drug Discovery  at Sanofi R&D providing scientific project support for drug discovery on a broad range of target proteins in the fields of small molecules and biotherapeutics. Anke is profoundly motivated by the human and by...

Stenner Frank, Prof. Dr., M.D.Since 12/2016 Head of the Hematology-Oncology Tumor Center (ZHO)/ BaselSince 06/2012 Senior Physician of Oncology at the University Hospital Basel, Switzerland11/2011-05/2012 Senior Physician of Oncology at the University Hospital Zurich11/2005-11/2011 Attending...

Dr. Pawel Stocki – Director of Research at Ossianix. At Ossianix we are utilising single domain shark antibody fragments to tackle the problem of therapeutic biologics delivery across Blood Brain Barrier. We focus on development and innovation of phage libraries and selection approaches, antibody...

Michael Streit, MD, MBA  is Executive Director and Clinical Development Leader in the Oncology Therapeutic Area of GlaxoSmithKline (GSK) in Collegeville, PA (USA).   Dr. Streit has a strong and diverse background in biomedical sciences. He received his medical degree and training in...

Dr. Strop received his Ph.D. from Caltech, where he elucidated structural mechanism of mechanosensitive ion channels. Afterwards, he moved to Stanford, where he studied proteins involved in synaptic neurotransmission. In 2008, he joined Rinat-Pfizer's protein engineering department where he...

Anish Suri is an immunologist with more than 20 years of experience in basic and translational research focused on immuno-oncology, autoimmune disorders, transplantation rejection, and inflammation. Prior to joining Cue Biopharma, he held roles of increasing responsibility at Janssen Pharmaceutical ...

Mathias holds a master’s in engineering in Molecular Biotechnology from Uppsala University and Ph.D. in molecular biology from Karolinska Institutet. He is a co-founder of the cord blood bank Cellaviva, established in 2014, a company that has evolved to NextCell Pharma AB which is developing stem...

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in the development of GPCR assay and the...

Huaping Tang is currently a Principal Scientist in the Bioanalytical (BA) Group within the Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism (PPDM) in Merck Research Laboratories. Since joining Merck, Huaping has been focusing on regulated PK and immunogenicity assays for...

Anne-Lise is Senior Research Officer in Analytical Development team, part of Process Sciences department of Glenmark Pharmaceuticals SA biologics R&D centre in La Chaux-de-Fonds, Switzerland. In her position, Anne-Lise has been involved in providing analytical services to various teams, from...

Dr. Tesi has been President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio since the formation of the Company in September 2015.  Dr. Tesi has been at the leadership level of biotech companies, both public and private since, 1997.  His industry experience has focused on...

BA diploma with focus on Production and Logistics from the University of Augsburg 3 Years Demand and Forecasting at Fujitsu Siemens Computer5 Years “Seihan” (fully integrated supply chain) Manager at Alpine Electronics7 Years Supply Chain Manager at Teva / Mepha Switzerland Since 2014 Head of...

Rob Thomas is an EPSRC Early Career Fellow and Professor in Manufacturing for Cell Based Therapies at Loughborough University. He leads a team developing the process science and technologies to enable manufacturing of cell based regenerative medicine therapies. The focus is efficient experimental...

Frédéric Triebel, MD. Ph.D., is the scientific founder of Immutep S.A. (2001). Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on...

Matthew Turner is the Senior Director European Government Affairs Biosimilars at Fresenius Kabi. Following basic lab research in oncology, he joined the pharmaceutical industry 25 years ago.  His career started with the leadership of clinical trials evaluating new drug entities from phase 1 through ...

Barbara, a MD and pharmacologist by training, has over 25year industry experience gained at Pharmacia, Pfizer, Whyet , Baxter and Baxalta in different medical, clinical, safety and regulatory roles working in local, regional and global organizations.  She holds the position of the Chief Medical...

Janet joined the Clinical Practice Research Datalink (CPRD) in 2015 as Director of the UK Government’s preeminent real-world research service supporting retrospective and prospective public health and clinical studies. Previously Janet spent 6 years as Head of Population Health and Health...

Thomas Valerius studied medicine at the University of Erlangen-Nürnberg, Germany. After his training in internal medicine, he specialized in hematology/oncology and rheumatology. Since May 2003, he has been working at the University in Kiel, Germany, where he currently is assistant professor at the ...

Medicines for Europe’s goal is to improve health by ensuring better access to treatment for patients in Europe and beyond. As Market Access Director for the Generic, Biosimilar and Value-Added medicines groups, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market...

Faidra van der Wal has a rich experience in clinical operations and global trial management.She is a GCDO Trial leader within Janssen, were she has been accountable for phase 3 pivotal studies in immunology.Having worked prior for a CRO as well as for a small biotech company, she has built up a...

Dr Sandrine Vessillier received her PhD in Biochemistry from the University Claude Bernard in Lyon. With a number of years of academic postdoctoral research at the William Harvey Research Institute in London she has developed a broad scientific base in Biochemistry, Enzymology, Immunology and...

Saskia Villinger got her diploma in biochemistry at the University of Frankfurt. She completed her doctoral degree and a post-doc at the Max-Planck-Institute for Biophysical Chemistry in Göttingen. During this period she studied structure, dynamics and interactions of a membrane protein by solution ...

Johannes vom Berg has been a junior group leader at the Institute of Laboratory Animal Science, University of Zurich, Switzerland since 2015. He also directed the mouse-transgenesis core facility of the University of Zurich from 2014-2018. He studied biology and molecular medicine in Freiburg im...

Ryuta Wada is a research scientist, Pharmaceutical Science & Technology Labs, Pharmaceutical Technology in Astellas Pharma, Inc. JAPAN. He has been working extensively on CMC laboratories, especially specializing in analytical development for mAb biotherapeutics, upstream cell line and process...

As the section leader for the Cytokines and Growth Factors Section, she is responsible for a number of diverse projects in these fields. These include preparation of World Health Organisation WHO international cytokine and growth factor standards and/or reference reagents, development and...

Simon Wandel holds a master in Statistics and a PhD in Medical Statistics/Epidemiology from University of Bern. In 2010, he joined Novartis as statistician. In 2013, he co-founded a start-up specialized for Bayesian statistics (Cogitars GmbH), before rejoining Novartis as Expert Statistical...

Stefan Warmuth, Ph.D. serves as Group Leader CMC and Therapeutic Program Leader at Numab Therapeutics, a Swiss biotech company with partnered as well as proprietary pipeline assets in the field of immuno-oncology and inflammatory diseases. He is responsible for the pharmaceutical development of...

Stefan Weigand, PhD, has been with Roche since 2005. He is currently Head of Large Molecule Research (LMR) at Roche pRED, responsible for Roche’s industry-leading efforts in biologics from concept to clinic. Prior to taking on this role in 2015, Stefan was Head of Biochemical and Analytical...

Robert leads an Oncology Research department based Granta Park (Cambridge, UK) and oversees pre-clinical oncology biologics research ranging from target identification to candidate drug selection and IND enabling support. Activities focus on utilising the latest biotherapeutic technologies...

Paula Williamson is Professor of Biostatistics. She is Director of the MRC North West Hub for Trials Methodology Research (HTMR), Director of the Clinical Trials Research Centre (CTRC), and Head of the Department of Biostatistics at the University of Liverpool. Paula chairs the University of...

Florian M. Wurm, trained as Biologist/Molecular/Geneticis. His career involved academic and industrial work: Behringwerke AG, Marburg (1981-1984), Harvard Boston (1984-1985), Genentech Inc, San Francisco (1986-1995), Swiss Federal Institute of Technology, Lausanne (EPFL), (1995-2015), ExcellGene...

Jens Wuerthner is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a licensed physician in Germany, Switzerland and the UK and a fellow of the Faculty of Pharmaceutical Medicine, UK.Dr. Wuerthner...

Research project team lead, and scientist in immunology drug discovery and translational research. Principal investigator and postdoc mentor managing a group of 5 Ph.D. level researchers fordeveloping small molecule compounds, peptides (cystine knot, and macrocyclic peptides), and novel antibodies...

Yingnan Zhang, Ph.D. in Biochemistry, is a Senior Scientific Manager at Genentech. She got her Ph.D in the field of enzymology and glycobiology from University of Miami, FL mentored by Dr. Keith Brew. She joined Genentech as a postdoc mentored by Dr. Sachdev Sidhu. She has been involved in many...

Jing joins Refuge Biotechnologies as Chief Business Officer following a wealth of experience in global healthcare transactions and financings. He has spent over a decade in pharmaceutical, biotech and healthcare finance working on a full spectrum of strategic transactions at big cap...

Stefan received his PhD in 2015 from the Technische Universität of Darmstadt, Germany, where he worked in the Group of Harald Kolmar in the field of protein engineering of non-canonical antibodies. During his PhD he spent some time at Scripps Institute, La Jolla (USA) working in the lab of Vaughn...